But the positive report, which matched Wall Street expectations, comes on the heels of a warning letter from the Food and Drug Administration that reprimands the company for failing to correct a longstanding defect in one of its drug infusion pumps.
FORBES: Medtronic Sees Revenue Growth Despite Unaddressed Quality Concerns